rs121918390 — APOB APOB R2522X

APOB R2522X — When Your Liver Makes Half an Apolipoprotein B

Apolipoprotein B (apoB) is the structural backbone of every LDL, VLDL, and chylomicron particle your liver makes. Without a full-length apoB-100, your liver cannot build and secrete normal LDL particles, so your circulating LDL cholesterol stays characteristically and permanently low¹¹ characteristically and permanently low
Heterozygous FHBL carriers almost always have LDL-C below 70 mg/dL regardless of diet, a lifelong trait caused by the variant, not by healthy lifestyle. This sounds like good news — and for cardiovascular health, it mostly is — but the same impaired lipid-export machinery creates two clinically relevant risks: fat accumulation in the liver and impaired transport of fat-soluble vitamins.

The Mechanism

The R2522X variant introduces a premature stop codon at amino acid 2,522 of the 4,536-amino-acid apoB-100 protein (c.7564C>T on the coding strand; G>A on the GRCh38 plus strand). The resulting truncated protein — called apoB-55²² apoB-55
The "55" refers to the fact that the truncated protein is approximately 55% the length of full-length apoB-100 — comprises about 55% of the normal protein length and is secreted at roughly 37–40% of the normal molar rate compared to wild-type apoB-100, consistent with the linear relationship between truncation length and secretion efficiency demonstrated by Parhofer et al.³³ demonstrated by Parhofer et al.
Parhofer et al. Positive linear correlation between the length of truncated apolipoprotein B and its secretion rate. J Lipid Res, 1996. The half of the protein that is missing includes domains critical for maximal lipid recruitment into the lipoprotein particle core.

Because apoB is the only structural protein on LDL particles, each cell carries one normal APOB allele and one truncating allele. The liver produces both full-length apoB-100 and the shorter apoB-55, but the truncated version carries less lipid cargo per particle, and fewer lipid-laden particles leave the liver — so hepatocytes accumulate triglycerides that cannot be exported.

The Evidence

The R2522X variant was first identified in the early 1990s in patients with unexplained low cholesterol. The same CGA→TGA change at the CpG dinucleotide hot spot in exon 26 was later independently rediscovered in a second kindred by Gabelli et al.⁴⁴ Gabelli et al.
Gabelli et al. Diabetes mellitus in a new kindred with familial hypobetalipoproteinemia and an apolipoprotein B truncation (apoB-55). Atherosclerosis, 1998, whose proband had LDL-C of 44 mg/dL and detectable plasma apoB-55 on immunoblotting. Notably, the proband and his father both had type 2 diabetes, yet neither had clinically manifest macrovascular complications — consistent with the cardiovascular-protective effect of lifelong low LDL-C.

The apoB-55 truncation falls in a zone where the protein can still be secreted and detected in plasma (unlike very short truncations below ~apoB-30, which are not detectable in plasma at all). Its secretion efficiency of ~37% of normal means heterozygotes lose roughly a third of their normal VLDL export capacity, explaining the 3-to-5-fold increase in hepatic fat content that characterizes FHBL, as reviewed by Schonfeld⁵⁵ Schonfeld
Schonfeld G. Familial hypobetalipoproteinemia: a review. J Lipid Res, 2003.

A systematic literature review by Molk et al.⁶⁶ Molk et al.
Molk et al. Non-alcoholic fatty liver disease in a pediatric patient with heterozygous familial hypobetalipoproteinemia due to a novel APOB variant. Front Med, 2023 confirms that fatty liver disease occurs even in heterozygous carriers and can present in childhood. About 5–10% of heterozygous FHBL individuals develop more severe nonalcoholic steatohepatitis requiring medical attention.

Practical Actions

For heterozygous carriers the most important immediate step is establishing a baseline: a fasting lipid panel confirms the expected low LDL-C and rules out concurrent dyslipidemia; liver enzymes (AST/ALT) and a hepatic ultrasound screen for steatosis; and serum levels of vitamins A, D, E, and K evaluate fat-soluble vitamin status. Because apoB-containing lipoprotein particles are the primary carriers of fat-soluble vitamins from the gut into circulation, impaired VLDL/chylomicron secretion can subtly reduce vitamin transport even when dietary intake is adequate. Supplementation with water-dispersible or emulsified forms of vitamins D, E, A, and K corrects any measured deficiency efficiently.

Dietary saturated fat restriction is not the goal here (unlike APOE4) — in fact, very low fat diets can worsen fat-soluble vitamin absorption. The aim is identifying and correcting any subclinical deficiency before it causes neurological or ophthalmological consequences.

Cardiovascular risk is paradoxically reduced: lifelong LDL-C below 70 mg/dL confers protection against atherosclerosis, and carriers need not take statins for lipid-lowering purposes. However, the reduced LDL does not protect against the metabolic consequences of obesity or insulin resistance, so maintaining a healthy metabolic profile remains relevant.

Interactions

In the rare case of a compound heterozygote or homozygote for APOB loss-of-function variants, the phenotype resembles abetalipoproteinemia (severe fat malabsorption, acanthocytosis, retinitis pigmentosa, progressive ataxia). Interaction with APOE genotype (rs429358, rs7412) is worth noting conceptually: APOE4 would ordinarily raise LDL cholesterol, but an APOB truncating variant overrides this by limiting the number of LDL particles produced rather than their clearance rate. The net effect in a double carrier would still be low LDL-C, driven by impaired production.